The $7.19M in post-quarter orders for FY 2028 is the key catalyst — watch for further order announcements and backlog growth in subsequent quarters as a lead indicator of revenue acceleration. The clean-energy headwind is structural (policy-driven) and likely to persist, so the medical segment must sustain >200% growth to offset it. Monitor the next 10-Q for guidance updates.
Price Chart
Executive Summary
Sono-Tek reported fiscal Q2 2027 results with net sales up 1% YoY to $5.23M, but operating income declined 9% and net income fell 14% to $366,000 ($0.02 EPS) — a miss vs the $0.05 consensus. The company reiterated flat-to-modest FY 2027 revenue guidance, though a strong medical segment (+209% in Q2) and a record $7.19M in post-quarter orders provide visibility into FY 2028. The mixed picture of a growing medical business offset by declining clean-energy sales and a guidance reiteration (not an upgrade) keeps the near-term outlook neutral.
Key Financial Metrics
Key Facts
- Q2 net sales $5.23M (+1% YoY); first-half sales $10.89M (+6% YoY)
- Q2 net income $366,000 ($0.02 diluted EPS) vs $424,000 ($0.03) a year ago — missed consensus of $0.05
- Medical market sales surged 209% in Q2 to $3.11M and 289% in 1H to $7.05M
- Alternative Energy sales collapsed 78% in Q2 to $535,000 and 85% in 1H to $855,000
- Backlog grew 23% sequentially to $9.51M; post-quarter orders of ~$7.19M expected to ship in FY 2028
- FY 2027 guidance reiterated as 'flat to modest revenue growth' — no upgrade
- Cash and marketable securities $17.7M, no debt
Financial Impact
Q2 EPS of $0.02 missed $0.05 consensus by 60%; revenue of $5.23M was in line with $5.2M consensus. Net income declined 14% YoY.
Risk Factors
- Continued decline in Alternative Energy sales due to U.S. policy shifts
- FY 2027 guidance of flat-to-modest growth implies no near-term acceleration
- EPS miss vs consensus may pressure the stock in the short term
- Quarterly revenue variability from large production platform orders
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171520-26-000304 |
| Document: eps12886_sotk.htm | 0001171520-26-000304 |
| Document: 0001171520-26-000304-index-headers.html | 0001171520-26-000304 |
| Document: 0001171520-26-000304-index.html | 0001171520-26-000304 |
| Document: 0001171520-26-000304.txt | 0001171520-26-000304 |
| 8-K Data (Synthetic) | 0001171520-26-000304 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 144 | $5.28 | awaiting T+60 | — | $5.14 (−2.65%) |
Oct 14, 2026 12d ago | 8-K | $6.21 | awaiting T+60 | — | $5.14 (−17.16%) |
Jul 27, 2026 13w ago | Insider Cluster | $5.11 $5.19 | ▲ +1.57% | ▼ −2.78% | $5.14 (+0.59%) |
Jul 8, 2026 15w ago | 8-K | $5.34 $5.82 | ▲ +8.99% | ▲ +6.49% | $5.14 (−3.75%) |
Jul 8, 2026 15w ago | Press Release | $5.34 $5.82 | ▲ +8.99% | ▲ +6.49% | $5.14 (−3.75%) |
May 28, 2026 21w ago | 8-K | $4.86 $5.48 | ▲ +12.65% | ▲ +10.92% | $5.14 (+5.76%) |
Mar 17, 2026 31w ago | Press Release | $4.18 $5.23 | ▲ +25.12% | ▲ +15.26% | $5.14 (+22.97%) |
Mar 11, 2026 32w ago | Press Release | $4.26 $5.25 | ▲ +23.24% | ▲ +11.72% | $5.14 (+20.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers